Our Team

Cancer Prevention Pharmaceuticals, Inc. was founded by Dr. Frank Meyskens and Dr. Gene Gerner, both of whom are highly respected cancer prevention researchers involved in some of the largest and most well-known oncology research institutions including the National Cancer Institute (NCI) and SWOG. CPP’s team has significant experience in drug development, regulatory and commercialization.

Board of Directors
Jeffrey Jacob
Chairman and CEO
Richard L. Love
Director
Eugene W. Gerner, PhD
Director and Chief Scientific Officer
Dan Donovan
Director and Chief Business Officer
Jon S. Saxe
Director
Management and Scientific Advisors
Alfred M. Cohen, MD, FACS, FASCRS
Chief Medical Officer
Christopher R. Richied
Chief Financial Officer
Kathryn Grenier MPA, HSA
VP of Clinical Operations
Marc L. Tokars
VP of Clinical and Regulatory Affairs
Elizabeth Bruckheimer, PhD
VP of Drug Development
Willene Brondum
Assoc. VP of Regulatory Affairs & Quality Assurance
Robert B. MacArthur, PharmD, MS
Senior Advisor, Product Development and Statistics
Stephen J. Rochelle, MS, RAC
Regulatory Affairs
Patrick Shannon, PhD
Project Management and CMC
Michelle Boytim, PhD
Program Manager, Clinical Research
Christine Brannen
Director of Operations